Dossier assessment

Olopatadine/mometasone (allergic rhinitis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-125
Last updated

Report documents

  1. Extract of dossier assessment

    Olopatadine/mometasone (allergic rhinitis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 318 kB, EN, not accessible
  2. Dossier assessment

    Olopatadine/mometasone (allergic rhinitis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 464 kB, DE, not accessible

Dossier assessment

Indication:

Adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2023-06-01 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A22-125
Commission
Commission awarded on 29.11.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Olopatadine/mometasone furoate (allergic rhinitis) – Addendum to Commission A22-125

    Project no.
    G23-09
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form